Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
PZ HTL SA
GLOBETECH PUBLISHING

GE Healthcare to Be Sole Distributor of Gyros' Nanoliter-Scale Immunoassay Platform in Japan

By BiotechDaily International staff writers
Posted on 20 Jul 2011
GE Healthcare Life Sciences (Little Chalfont, UK), a global provider of transformational medical technologies and services, has signed a sole distribution agreement with Gyros AB (Uppsala, Sweden), a developer of microfluidic technologies to miniaturize and automate immunoassays. Under the agreement, GE Healthcare becomes the sole distributor of the Gyros nanoliter-scale immunoassay platform in Japan.

Major biopharmaceutical companies and their service providers use the Gyros platform worldwide to improve productivity and efficiency when developing biotherapeutics and vaccines, generating time-critical workflows to meet regulatory demands.

Erik Walldén, CEO at Gyros, said, “The growing acceptance of our nanoliter-scale immunoassay platform within the global biopharmaceutical industry makes it imperative that we are represented within the Japanese market. We believe that this agreement with GE Healthcare Life Sciences will be a key factor in our success. As well as the clear commercial synergy between our product portfolios, we can be sure of providing the highest standards of service and support for our Japanese customers. We look forward to a highly successful collaboration.”

Hiroko Watanabe, general manager GE Healthcare Life Sciences, Japan, added, “We are delighted to have signed this agreement with Gyros which will help us expand our offering of value-added and innovative technologies to the biopharmaceutical industry in Japan. The Gyros immunoassay platform offers manufacturers of biopharmaceuticals and vaccines the potential to make substantial improvements in productivity and is an excellent complement to our own extensive range of analytical technologies for the biopharmaceutical industry.”

Related Links:

GE Healthcare Life Sciences
Gyros



Channels

Genomics/Proteomics

view channel
Image: Biopsy of small bowel showing celiac disease manifested by blunting of villi, crypt hyperplasia, and lymphocyte infiltration of crypts (Photo courtesy of Wikimedia Commons).

Reduced Elafin Levels Associated with Celiac Disease Bowel Inflammation

Levels of the enzyme elafin, an endogenous serine protease inhibitor, were lower in the small intestinal epithelium of patients with active celiac disease (CD) as compared to similar tissue from control patients.... Read more

Drug Discovery

view channel

Retinoic Acid Prevents Precancerous Breast Cells from Progressing to Full-Blown Cancer

Retinoic acid, a derivative of vitamin A, was found to prevent pre-cancerous breast cells from progressing to full-blown cancer but did not have any effect on breast tumor cells. Investigators at Thomas Jefferson University (Philadelphia, PA, USA) worked with a novel breast cancer model that had been developed by treating... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.